|
1
|
Campiani G, Nacci V, Fiorini I, De
Filippis MP, Garofalo A, Ciani SM, Greco G, Novellino E, Williams
DC, Zisterer DM, et al: Synthesis, biological activity, and SARs of
pyrrolobenzoxazepine derivatives, a new class of specific
‘peripheral-type’ benzodiazepine receptor ligands. J Med Chem.
39:3435–3450. 1996.PubMed/NCBI
|
|
2
|
Zisterer DM, McGee MM, Campiani G, Ramunno
A, Fattorusso C, Nacci V, Lawler M and Williams DC:
Pyrrolo-1,5-benzoxazepines: a new class of apoptotic agents.
Biochem Soc Trans. 29:704–706. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mulligan JM, Greene LM, Cloonan S, McGee
MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC and
Zisterer DM: Identification of tubulin as the molecular target of
proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol. 70:60–70.
2006.PubMed/NCBI
|
|
4
|
McGee MM, Greene LM, Ledwidge S, Campiani
G, Nacci V, Lawler M, Williams DC and Zisterer DM: Selective
induction of apoptosis by the pyrrolo-1,5-benzoxazepine
7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d]
(1,5)-benzoxazepine (PBOX-6) in leukemia cells occurs via the c-Jun
NH2-terminal kinase-dependent phosphorylation and inactivation of
Bcl-2 and Bcl-XL. J Pharmacol Exp Ther. 310:1084–1095.
2004.PubMed/NCBI
|
|
5
|
Greene LM, Fleeton M, Mulligan J, Gowda C,
Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC,
et al: The pyrrolo-1, 5-benzoxazepine, PBOX-6, inhibits the growth
of breast cancer cells in vitro independent of estrogen
receptor status and inhibits breast tumour growth in vivo.
Oncol Rep. 14:1357–1363. 2005.PubMed/NCBI
|
|
6
|
Greene LM, Campiani G, Lawler M, Williams
DC and Zisterer DM: BubR1 is required for a sustained mitotic
spindle checkpoint arrest in human cancer cells treated with
tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol.
73:419–430. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nathwani SM, Butler S, Fayne D, McGovern
NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams
DC, et al: Novel microtubule-targeting agents,
pyrrolo-1,5-benzoxazepines, induce apoptosis in
multi-drug-resistant cancer cells. Cancer Chemother Pharmacol.
66:585–596. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McElligott AM, Maginn EN, Greene LM,
McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood
MA, Vandenberghe E, et al: The novel tubulin-targeting agent
pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic
subgroups of chronic lymphocytic leukemia. Cancer Res.
69:8366–8375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bright SA, McElligott AM, O’Connell JW,
O’Connor L, Carroll P, Campiani G, Deininger MW, Conneally E,
Lawler M, Williams DC, et al: Novel pyrrolo-1,5-benzoxazepine
compounds display significant activity against resistant chronic
myeloid leukaemia cells in vitro, in ex vivo patient samples and in
vivo. Br J Cancer. 102:1474–1482. 2010. View Article : Google Scholar
|
|
10
|
Nathwani SM, Butler S, Meegan MJ, Campiani
G, Lawler M, Williams DC and Zisterer DM: Dual targeting of tumour
cells and host endothelial cells by novel microtubule-targeting
agents, pyrrolo-1,5-benzoxazepines. Cancer Chemother Pharmacol.
65:289–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sato K, Tsuchihara K, Fujii S, Sugiyama M,
Goya T, Atomi Y, Ueno T, Ochiai A and Esumi H: Autophagy is
activated in colorectal cancer cells and contributes to the
tolerance to nutrient deprivation. Cancer Res. 67:9677–9684. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu YC, Wang XJ, Yu L, Chan FK, Cheng AS,
Yu J, Sung JJ, Wu WK and Cho CH: Hydrogen sulfide lowers
proliferation and induces protective autophagy in colon epithelial
cells. PLoS One. 7:e375722012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li DD, Sun T, Wu XQ, Chen SP, Deng R,
Jiang S, Feng GK, Pan JX, Zhang XS, Zeng YX, et al: The inhibition
of autophagy sensitises colon cancer cells with wild-type p53 but
not mutant p53 to topotecan treatment. PLoS One. 7:e450582012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paillas S, Causse A, Marzi L, de Medina P,
Poirot M, Denis V, Vezzio-Vie N, Espert L, Arzouk H, Coquelle A, et
al: MAPK14/p38alpha confers irinotecan resistance to TP53-defective
cells by inducing survival autophagy. Autophagy. 8:1098–1112. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ravikumar B, Sarkar S, Davies JE, Futter
M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M,
Korolchuk VI, Lichtenberg M, Luo S, et al: Regulation of mammalian
autophagy in physiology and pathophysiology. Physiol Rev.
90:1383–1435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han W, Sun J, Feng L, Wang K, Li D, Pan Q,
Chen Y, Jin W, Wang X, Pan H, et al: Autophagy inhibition enhances
daunorubicin-induced apoptosis in K562 cells. PLoS One.
6:e284912011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen S, Kepp O and Kroemer G: The end of
autophagic cell death? Autophagy. 8:1–3. 2012. View Article : Google Scholar
|
|
19
|
Greene LM, O’Boyle NM, Nolan DP, Meegan MJ
and Zisterer DM: The vascular targeting agent Combretastatin-A4
directly induces autophagy in adenocarcinoma-derived colon cancer
cells. Biochem Pharmacol. 84:612–624. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cook KL, Shajahan AN and Clarke R:
Autophagy and endocrine resistance in breast cancer. Expert Rev
Anticancer Ther. 11:1283–1294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zois CE and Koukourakis MI:
Radiation-induced autophagy in normal and cancer cells: towards
novel cytoprotection and radio-sensitization policies? Autophagy.
5:442–450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Clarke PG and Puyal J: Autophagic cell
death exists. Autophagy. 8:867–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Boya P, Gonzalez-Polo RA, Casares N,
Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D,
Souquere S, Yoshimori T, et al: Inhibition of macroautophagy
triggers apoptosis. Mol Cell Biol. 25:1025–1040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu YC, Wu WK, Li Y, Yu L, Li ZJ, Wong CC,
Li HT, Sung JJ and Cho CH: Inhibition of macroautophagy by
bafilomycin A1 lowers proliferation and induces apoptosis in colon
cancer cells. Biochem Biophys Res Commun. 382:451–456. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bing L, Dejuan K, Yang L, Nan L, Mengzi H,
Shumei M and Xiaodong L: Autophagy inhibition plays the synergetic
killing roles with radiation in the multi-drug resistant SKVCR
ovarian cancer cells. Radiat Oncol. 7:2132012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu S, Cao L, Yu Y, Yang L, Yang M, Liu K,
Huang J, Kang R, Livesey KM and Tang D: Inhibiting autophagy
potentiates the anticancer activity of IFNα in chronic myeloid
leukemia cells. Autophagy. 9:317–327. 2012.PubMed/NCBI
|
|
27
|
Swampillai AL, Salomoni P and Short SC:
The role of autophagy in clinical practice. Clin Oncol (R Coll
Radiol). 24:387–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cerniglia GJ, Karar J, Tyagi S,
Christofidou-Solomidou M, Rengan R, Koumenis C and Maity A:
Inhibition of autophagy as a strategy to augment radiosensitization
by the dual phosphatidylinositol 3-kinase/mammalian target of
rapamycin inhibitor NVP-BEZ235. Mol Pharmacol. 82:1230–1240. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maycotte P and Thorburn A: Autophagy and
cancer therapy. Cancer Biol Ther. 11:127–137. 2011. View Article : Google Scholar
|
|
32
|
Nakatogawa H, Suzuki K, Kamada Y and
Ohsumi Y: Dynamics and diversity in autophagy mechanisms: lessons
from yeast. Nat Rev Mol Cell Biol. 10:458–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamamoto A, Tagawa Y, Yoshimori T,
Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents
maturation of autophagic vacuoles by inhibiting fusion between
autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E
cells. Cell Struct Funct. 23:33–42. 1998. View Article : Google Scholar
|
|
34
|
Jahreiss L, Menzies FM and Rubinsztein DC:
The itinerary of autophagosomes: from peripheral formation to
kiss-and-run fusion with lysosomes. Traffic. 9:574–587. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Klionsky DJ, Elazar Z, Seglen PO and
Rubinsztein DC: Does bafilomycin A1 block the fusion of
autophagosomes with lysosomes? Autophagy. 4:849–950. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maginn EN, Browne PV, Hayden P,
Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani
G, Butini S, et al: PBOX-15, a novel microtubule targeting agent,
induces apoptosis, upregulates death receptors, and potentiates
TRAIL-mediated apoptosis in multiple myeloma cells. Br J Cancer.
104:281–289. 2011. View Article : Google Scholar
|
|
37
|
Greene LM, Kelly L, Onnis V, Campiani G,
Lawler M, Williams DC and Zisterer DM: STI-571 (imatinib mesylate)
enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a
novel microtubule-targeting agent, in both STI-571-sensitive and
-resistant Bcr-Abl-positive human chronic myeloid leukemia cells. J
Pharmacol Exp Ther. 321:288–297. 2007. View Article : Google Scholar
|
|
38
|
Bright SA, Greene LM, Greene TF, Campiani
G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC and
Zisterer DM: The novel pyrrolo-1, 5-benzoxazepine, PBOX-21,
potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in
human chronic myeloid leukaemia cells. Biochem Pharmacol.
77:310–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bright SA, Campiani G, Deininger MW,
Lawler M, Williams DC and Zisterer DM: Sequential treatment with
flavopiridol synergistically enhances
pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic
myeloid leukaemia cells including those resistant to imatinib
treatment. Biochem Pharmacol. 80:31–38. 2010. View Article : Google Scholar
|
|
40
|
Nathwani SM, Cloonan SM, Stronach M,
Campiani G, Lawler M, Williams DC and Zisterer DM: Novel
microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce
cell cycle arrest and apoptosis in prostate cancer cells. Oncol
Rep. 24:1499–1507. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Forde JC, Maginn EN, McNamara G, Martin
LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M,
Lynch TH, et al: Microtubule-targeting-compound PBOX-15
radiosensitizes cancer cells in vitro. Cancer Biol Ther.
11:421–428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kimura T, Takabatake Y, Takahashi A and
Isaka Y: Chloroquine in cancer therapy: a double-edged sword of
autophagy. Cancer Res. 73:3–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Trmcic MV, Matovic RV, Tovilovic GI,
Ristic BZ, Trajkovic VS, Ferjancic ZB and Saicic RN: A novel
C,D-spirolactone analogue of paclitaxel: autophagy instead of
apoptosis as a previously unknown mechanism of cytotoxic action for
taxoids. Org Biomol Chem. 25:4933–4942. 2012. View Article : Google Scholar
|
|
44
|
Kanematsu S, Uehara N, Miki H, Yoshizawa
K, Kawanaka A, Yuri T and Tsubura A: Autophagy inhibition enhances
sulforaphane-induced apoptosis in human breast cancer cells.
Anticancer Res. 30:3381–3390. 2010.PubMed/NCBI
|
|
45
|
Sasazawa Y, Futamura Y, Tashiro E and
Imoto M: Vacuolar H+-ATPase inhibitors overcome
Bcl-xL-mediated chemoresistance through restoration of a
caspase-independent apoptotic pathway. Cancer Sci. 100:1460–1467.
2009.
|
|
46
|
Hettiarachchi KD, Zimmet PZ and Myers MA:
The plecomacrolide vacuolar-ATPase inhibitor bafilomycin, alters
insulin signaling in MIN6 beta-cells. Cell Biol Toxicol.
22:169–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pliyev BK and Menshikov M: Differential
effects of the autophagy inhibitors 3-methyladenine and chloroquine
on spontaneous and TNF-alpha-induced neutrophil apoptosis.
Apoptosis. 17:1050–1065. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rubinstein AD, Eisenstein M, Ber Y, Bialik
S and Kimchi A: The autophagy protein Atg12 associates with
antiapoptotic Bcl-2 family members to promote mitochondrial
apoptosis. Mol Cell. 44:698–709. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Luo S and Rubinsztein DC: BCL2L11/BIM: A
novel molecular link between autophagy and apoptosis. Autophagy.
9:104–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huynh KK, Eskelinen EL, Scott CC,
Malevanets A, Saftig P and Grinstein S: LAMP proteins are required
for fusion of lysosomes with phagosomes. EMBO J. 26:313–324. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kundra R and Kornfeld S: Asparagine-linked
oligosaccharides protect Lamp-1 and Lamp-2 from intracellular
proteolysis. J Biol Chem. 274:31039–31046. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yogalingam G and Pendergast AM: Abl
kinases regulate autophagy by promoting the trafficking and
function of lysosomal components. J Biol Chem. 283:35941–35953.
2008. View Article : Google Scholar : PubMed/NCBI
|
